We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Pandemic hedge

12 April 2021 By Lisa Jucca

The Italian diagnostic group which has benefited from pandemic demand is buying smaller U.S. peer Luminex for $1.8 bln. Thanks to hefty cost savings the deal makes financial sense. With vaccinations accelerating, it’s a good time to seek more enduring sources of revenue.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)